Organon & Co. (OGN) — Analysis Summary
Organon & Co. (OGN) has a market cap of $3.58B with year-over-year revenue growth of -2.9%. Net margin stands at 3.0%. The stock trades at a P/E ratio of 17.2.
Key Takeaways
- Revenue changed -2.9% year-over-year
- Net margin of 3.0%
- P/E ratio of 17.2
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, OGN posted revenue growth of -2.9% and trades at a P/E of 17.2.
Organon & Co. (OGN)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 7.7x — highly leveraged, potential refinancing risk
Interest coverage at 0.0x — earnings do not cover interest payments
D/E at 8.5x — extreme leverage
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
10,000
Headquarters
JERSEY CITY, NJ
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.08
Dividend Yield
0.59%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.